govt.chinadaily.com.cn

Home> Topics > Medical Products > Drugs

NMPA issues the Announcement on Adjusting the Relevant Matters Concerning the Definition of the Attributes of Drug/Device Combination Products

CDE releases the List of the Second Batch of Overseas New Drugs Urgently Needed in Clinical Settings

NMPA issues the Announcement on Issues Concerning the Import of Reference Drugs for Clinical Research of Biosimilar Drugs

SAMR issues the Measures for the Administration of Imported Medicinal Materials

Provisions for Post-approval Changes of Drugs (Interim)

Provisions for the Supervision and Administration of Drug Manufacturing

Provisions for Drug Registration

Provisions for Crude Drugs Importation

Good Supply Practice for Drugs

Provisions for Unannounced Inspection of Drugs and Medical Devices (Decree No.14 of China Food and Drug

Provisions for Drug Recall (SFDA Decree No. 29)

Provisions for the Lot Release of Biological Products (CFDA Decree No.39)

Decree of State Food and Drug Administration

NMPA issues the Guiding Principles for Capacity Building of Drug Inspection and Testing Institutions

NMPA issues three informationization standards such as the Basic Technical Requirements for Drug Traceability System

Newly revised drug administration law adopted After deliberation

China revises law to ensure drug safety

NMPA issues the Administrative Measures for Drug Quality Sampling Inspection

Announcement of the National Medical Products Administration, the Ministry of Public Security, and the National Health Commission, on the Inclusion of Varieties including Oxycodone-containing Medicines as Psychotropic Drugs

NMPA issues the Notice on Enabling the New Version of the Drug Production License and other Certificates

1 2 >

MOST POPULAR

Editors' Picks

LEAVE YOUR MESSAGE

*Your E-mail Address

Copyright©2025 China Daily. All rights reserved.

京ICP备13028878号-6

京公网安备 11010502032503号 京公网安备 11010502032503号

站长统计